DigestRedComo funciona
Red
/
Empresas
Mo
No verificado

Molecular Targeting Technologies, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaOncologíaSalud

11 Comunicados de prensa

Ver todos los comunicados de prensa
22/09/2026
Mercado laboral
Oncología
Salud
Sanidad
Ciencia
Farmacéutica
Biotecnología
MTTI Awarded $3.17 Million NCI Grant to Advance ¹⁷⁷Lu-EBRGD Development for Non-Small Cell Lung Cancer
Fuente
Molecular Targeting Technologies, Inc.
Editor
Business Wire
1.00
0
01/09/2026
Eventos
Industria
Oncología
Salud
Sanidad
Medicina nuclear
Farmacéutica
Biotecnología
Molecular Targeting Technologies Receives Pharma Tech Outlook’s 2026 “Radiopharmaceutical Therapy Solution of the Year” Award for EvaThera™
Fuente
Molecular Targeting Technologies, Inc.
Editor
Business Wire
1.00
0
07/07/2026
Eventos
Industria
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Molecular Targeting Technologies Presents First Clinical Validation of the Evans Blue Platform, Demonstrating Up to 15-Day Tumor Retention Using Approximately 12.5% of the Radioactivity Required for Conventional PRRT
Fuente
Molecular Targeting Technologies, Inc.
Editor
Business Wire
1.00
0
10/06/2026
Ferias y Congresos
Eventos
Industria
Biotecnología
Medicina nuclear
Salud
Oncología
MTTI Highlights Clinical Experience in 81 GEP-NETs Patients and Differentiated Profile of Next-Generation PRRT Candidate EBTATE Following Presentation at SNMMI 2026
Fuente
Molecular Targeting Technologies, Inc.
Editor
Business Wire
1.00
0
28/05/2026
Biotecnología
Sanidad
Salud
Medicina - Varios
Oncología
Industria
Molecular Targeting Technologies Reports Clinical Data Supporting Two-Cycle EBTATE and Enhanced Tumor Targeting in GEP-NET Patients at SNMMI 2026
Fuente
Molecular Targeting Technologies, Inc.
Editor
Business Wire
1.00
0
14/10/2025
Oncología
Asociaciones/Profesionales
Salud
Legislación/Derecho
Medicina nuclear
Farmacéutica
Biotecnología
Industria
Molecular Targeting Technologies, Inc. Initiates Legal Action Over Unauthorized Use of Albumin-binding Evans blue Targeted Radiotherapeutic (EB-TRT)
Fuente
Molecular Targeting Technologies, Inc.
Editor
Business Wire
1.00
0
10/10/2025
Asociaciones/Profesionales
Salud
Legislación/Derecho
Ciencia
Sanidad
Molecular Targeting Technologies, Inc. Initiates Legal Action Over Unauthorized Use of Albumin-binding Evans blue (EB) Targeted Radiotherapeutic (EB-TRT)
Fuente
Molecular Targeting Technologies, Inc.
Editor
Business Wire
1.00
0
22/07/2025
Salud
Medicina - Varios
Sanidad
Medicina nuclear
Farmacéutica
Biotecnología
Mercado laboral
MTTI Announces Dr. Danielle Meyrick to Lead Medical Team
Fuente
Molecular Targeting Technologies, Inc.
Editor
Business Wire
1.00
0
09/12/2024
Industria
Universidad
Biotecnología
Escuela/Educación
Salud
Libros/Industria editorial
Medicina nuclear
Farmacéutica
Oncología
Comunicación
Medicina - Varios
MTTI 225Ac-EBTATE is Highly Effective Against Neuroendocrine Tumors
Fuente
Molecular Targeting Technologies, Inc.
Editor
Business Wire
1.00
0
12/09/2024
Eventos
Industria
Ciencia
Medicina nuclear
Biotecnología
Farmacéutica
Oncología
Salud
Material médico sanitario
MTTI Reports on Fast-Acting Sprayable Molecule to Visualize Tumors for Real-Time Fluorescence-Guided Cytoreductive Surgery
Fuente
Molecular Targeting Technologies, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0